Varicella vaccine programs


Volume 41-10, October 1, 2015: Vaccines


A spot of bother: Why varicella vaccine programs matter

Harris T1*, Seo CY1, Shing E2, Wong K1, Fediurek J1, Deeks SL1,2


1 Public Health Ontario, Toronto, ON

2 Dalla Lana School of Public Health, University of Toronto, Toronto, ON




Objective: To evaluate Ontario's provincial varicella vaccination program through analysis of aggregate varicella cases in order to determine whether there has been a decrease in reportable disease burden; and to assess varicella vaccine adverse events following immunization (AEFIs).

Methods: Aggregate varicella cases (1993-2013) were extracted from the reportable disease databases. Pre-program (1993-2004) and post-program (2007-2013) periods were chosen according to implementation of the publicly funded vaccination program. AEFIs following administration of varicella vaccines (2010-2013) were also extracted. Reporting rates were calculated using net doses distributed as the denominator. Serious AEFIs were defined using World Health Organization standards.

Results: The incidence of aggregate varicella reports decreased significantly over the study period (from 311.4 to 22.2 cases per 100,000 population in 1993 and 2013, respectively). Incidence also decreased significantly in all age groups between the pre- and the post-program periods with a shift in age distribution towards older individuals in the post-program period. A total of 162 AEFIs following varicella vaccine were reported between 2010 and 2013 for an annualized reporting rate of 14.6 per 100,000 doses distributed. The most common events were rash (37.3%), including eight reports of varicella-like rash (0.7 per 100,000 doses distributed). Ten serious events were reported (0.9 per 100,000 doses distributed), and all vaccine recipients recovered.

Conclusion: Significant reductions in varicella disease incidence and low AEFI reporting rates were observed with the introduction of the publicly funded varicella vaccine program in Ontario. Continued surveillance is indicated to further assess trends in varicella disease and vaccine safety.


Varicella, commonly known as chickenpox, is a primary infection caused by the varicella-zoster virus (VZV). Prior to the introduction of varicella vaccines, chickenpox was considered a ubiquitous disease of childhood affecting 90% of children by 12 years of ageFootnote 1. Before varicella vaccines were available in Canada, approximately 350,000 varicella cases occurred each year with over 1,550 hospitalizations annually for all ages between 1994 and 2000Footnote 1. In addition, 59 varicella-related deaths were reported throughout the country between 1987 and 1997Footnote 1.

Live, attenuated varicella vaccine was first authorized for use in Canada in 1998, and was available for private purchase in OntarioFootnote 2. In September 2004, a single dose of varicella vaccine (Varilrix® [GlaxoSmithKline-GSK] or Varivax® III [Merck]) was added to Ontario's publicly funded immunization schedule for children 15 months of age. In August 2011, a second dose was added to the provincial schedule, administered as measles-mumps-rubella-varicella (MMRV) vaccine (Priorix-Tetra® [GSK]) at 4 to 6 years of ageFootnote 3. In addition, children born on or after January 1, 2000, who were at least 1 year of age were eligible for a second dose of varicella vaccineFootnote 4. One-dose varicella vaccine coverage was 77.8% among 5-year-olds in Ontario based on coverage assessment of school pupils for the 2012-2013 school yearFootnote 5.

With the implementation of universal childhood varicella immunization programs, a decrease in disease incidence and varicella-related hospitalizations has been observed in CanadaFootnote 6Footnote 7Footnote 8Footnote 9Footnote 10 and the United StatesFootnote 11Footnote 12Footnote 13Footnote 14. Decreases in varicella incidence and morbidity have also been observed in Australia and some European countries (e.g., Germany; parts of Italy and Spain) after the implementation of varicella vaccination programsFootnote 15Footnote 16Footnote 17. Extensive post-marketing surveillance of varicella vaccine safety over almost two decades has demonstrated an excellent safety profile where the majority of reported events are mild, including fever, rash and injection site reactions, and serious events are rareFootnote 18Footnote 19Footnote 20Footnote 21.

Assessment of immunization coverage, disease surveillance and vaccine safety data are essential components of comprehensive immunization program evaluation. Our objective is to evaluate the provincial varicella vaccination program through the analysis of aggregate reports of varicella cases throughout the period of program implementation, from 1993 to 2013; and the assessment of adverse events reported following administration of varicella-containing vaccines administered in Ontario between 2010 and 2013.


In Ontario, reporting of varicella and adverse events following immunization (AEFIs) to the local medical officer of health is mandated by provincial public health legislation. Local public health units (PHUs) investigate reports and enter information according to provincial surveillance guidelines into the integrated Public Health Information System (iPHIS), the electronic reporting system for reportable diseases and AEFIs in Ontario. Varicella is reported as both individual cases and in aggregate numbers in iPHIS. All PHUs are required to report monthly aggregate counts by predefined age groups, as well as individually reporting cases that are laboratory-confirmed, hospitalized or have specified complications, including deathFootnote 22Footnote 23Footnote 24. Aggregate cases do not contain individual-level case details; they contain only information on age group, PHU, year and month of reporting. Herpes zoster is not a reportable disease in Ontario.

Aggregate varicella reporting

Our analyses were limited to aggregate cases of varicella reported between January 1993 and December 2013. Individually reported cases of varicella were not included in the study. We extracted aggregate cases reported between 1993 and 2004 from the Ontario Public Health Portal on May 24, 2012, and aggregate cases reported between 2007 and 2013 from iPHIS on July 16, 2014. We excluded cases from 2005 and 2006 due to data completeness issues arising from transition in Ontario's reportable disease databases (from the Reportable Disease Information System to iPHIS). We selected pre- (1993-2004) and post- (2007-2013) publicly funded program periods based on the dates of implementation of the publicly funded varicella vaccination program in Ontario. The pre-program period includes time when varicella vaccine was available for private purchase, but not publicly funded (excluding the last four months of 2004). Incidence rate ratios (IRRs) were calculated to examine the changes in disease incidence between the two periods (i.e., the incidence rate in the post-program period divided by the incidence rate in the pre-program period). Trends in incidence rate over the entire study period were assessed using Poisson regression.

Adverse events following immunization

On April 28, 2014, we extracted from iPHIS all AEFIs reported following administration of varicella-containing vaccines (monovalent varicella vaccines and MMRV vaccine) between January 1, 2010, and December 31, 2013. Descriptive analyses were limited to "confirmed" AEFIs which are defined as events that follow immunization which cannot be attributed to other causes. A causal relationship with the vaccine does not need to be proven.

Each AEFI report represents one vaccine recipient and one or more adverse events temporally associated with receipt of one or more vaccines. Adverse events were grouped by provincial case definitions. We selected age categories for analysis based on the recommended routine varicella immunization scheduleFootnote 3. Reporting rates are calculated using net doses distributed within the publicly funded program as the denominator. We defined serious AEFIs using the Public Health Agency of Canada AEFI reporting guidelines which are based on the World Health Organization standard definitionFootnote 25Footnote 26. We conducted a key-word search of narrative case notes to identify varicella- or zoster-like rashes. Monovalent varicella and MMRV vaccine AEFIs are presented separately.

We performed statistical analyses using SAS (Statistical Analysis System) version 9.3 and Microsoft Excel 2010; p-values less than 0.05 were considered statistically significant.


Aggregate varicella reporting

Between January 1993 and December 2013, a total of 295,928 aggregate varicella cases were reported in Ontario. Varicella incidence decreased significantly over the study period from 311.4 cases per 100,000 population in 1993 to 22.2 cases per 100,000 population in 2013 (Figure 1).

Figure 1: Number of aggregate varicella cases and incidence in Ontario, 1993-2013 (n=295,928)

Figure 1: Number of aggregate varicella cases and incidence in Ontario, 1993-2013 (n=295,928)

Text description: Figure 1

Figure 1: Number of aggregate varicella cases and incidence in Ontario, 1993-2013 (n=295,928)

Year Population Count Rate
1993 10,690,447 33,289 311.4
1994 10,827,501 27,826 257.0
1995 10,964,925 28,229 257.4
1996 11,082,903 12,351 111.4
1997 11,227,651 20,695 184.3
1998 11,365,901 21,950 193.1
1999 11,504,759 16,700 145.2
2000 11,683,290 26,812 229.5
2001 11,897,370 12,319 103.5
2002 12,093,299 16,274 134.6
2003 12,243,758 14,743 120.4
2004 12,390,068 17,819 143.8
2005 12,527,990    
2006 12,661,566    
2007 12,764,195 10,161 79.6
2008 12,882,625 8,165 63.4
2009 12,997,687 7,524 57.9
2010 13,135,063 7,980 60.8
2011 13,263,544 5,549 41.8
2012 13,411,994 4,535 33.8
2013 13,537,994 3,007 22.2

Between the pre- and post-program periods, the overall incidence of varicella decreased from 180.5 to 51.0 cases per 100,000 population, for an IRR of 0.28 [95% confidence interval (CI): 0.28-0.29]. There was also a decrease in age-specific incidence which was significant in all age groups. The largest decline was observed in children in the 1- to 4-year-old age group, followed by the 5- to 9- and less than 1-year-old age groups (Table 1). In terms of age distribution, the 5- to 9-year-old age group continued to have the highest proportion of total varicella cases (57% in both periods); however, a shift in distribution towards older individuals was noted in the post-program period. Between the two periods, the proportion of cases among the 10- to 14-year-olds increased from 10.8% to 19.8%, while the proportion among the 1- to 4-year-olds decreased from 26.1% to 15.8%.

Table 1: Varicella incidence rate ratios comparing the pre-program period to the post-program period, by age group in Ontario, 1993-2013
Age group (years) Pre-program incidence
(per 100,000 population)
Post-program incidence
(per 100,000 population)
Incidence rate ratio
(95% confidence interval)
Overall 180.5 51.0 0.28 (0.28-0.29)
<1 137.1 50.3 0.37 (0.33−0.40)
01-04 899.9 183.9 0.20 (0.20−0.21)
05-09 1,506.3 520.6 0.35 (0.34−0.35)
10-14 282.0 167.6 0.59 (0.58−0.61)
15-19 58.1 21.2 0.36 (0.34−0.39)
≥20 6.5 2.7 0.41 (0.39−0.43)

Adverse events following immunization

Monovalent varicella vaccine AEFIs

There were 162 confirmed AEFIs reported following administration of monovalent varicella vaccine and 1,106,143 doses of varicella vaccine distributed between January 1, 2010, and December 31, 2013. The annualized reporting rate was 14.6 per 100,000 doses distributed, and steadily increased from 10.9 per 100,000 doses distributed in 2010 to 19.1 per 100,000 doses distributed in 2013 (Figure 2). The age range was from 9 months to 70 years (median: 4.5 years); 38.9% of reports occurred in children between 12 and 23 months of age. Overall, 52.5% of AEFI reports were female; however, among adults over 18 years, 92.9% (n=13) were female.

Figure 2: Number of AEFIs reported following administration of monovalent varicella vaccines and reporting rate per 100,000 doses distributed in Ontario, by year, 2010-2013

Figure 2: Number of AEFIs reported following administration of monovalent varicella vaccines and reporting rate per 100,000 doses distributed in Ontario, by year, 2010-2013

Text description: Figure 2

Figure 2: Number of AEFIs reported following administration of monovalent varicella vaccines and reporting rate per 100,000 doses distributed in Ontario, by year, 2010-2013

Year Confirmed AEFI Doses distributed Reporting rate
2010 17 156,044 10.89
2011 32 279,076 11.46
2012 55 367,879 14.95
2013 58 303,144 19.13

Monovalent varicella vaccines were administered alone in 62.3% (n=101) of reports. Rash was the most commonly reported event (37.3%), followed by pain, redness or swelling at the injection site (32.9%) (Table 2). Key-word searching of case notes identified eight reports that described varicella-like rashes—all following the first dose of vaccine with a median time to onset of 7.5 days (range: 2 to 17 days). Seven of these events occurred in children between 12 and 23 months of age and one occurred in an adolescent; none were laboratory-confirmed. There was also one report of laboratory-confirmed herpes zoster infection in a toddler with zoster-like symptoms 6.5 months after the first dose of vaccine. Genotyping confirmed vaccine-strain varicella zoster virus isolated from a skin specimen.

Table 2: Number and distribution of varicella vaccine AEFIs in Ontario, by adverse event category, 2010-2013
Adverse event categoryTable 2 - Footnote 1 Adverse eventTable 2 - Footnote 2 All AEFI reports
n (%)Table 2 - Footnote 3
Serious AEFIs
n (%)Table 2 - Footnote 4
Reporting rate
(per 100,000 doses distributed)
Serious reporting rate
(per 100,000 doses distributed)
Allergic events Total 37 (23.0) 2 (5.4) 3.3 0.2
  • Allergic reaction—other
2 (1.2) 0 (0.0) 0.2 0
  • Allergic reaction—skin
33 (20.5) 1 (3.0) 3.0 0.1
  • Event managed as anaphylaxis
2 (1.2) 1 (50) 0.2 0.1
Injection site reactions Total 76 (47.2) 2 (2.6) 6.9 0.2
  • Cellulitis
18 (11.2) 2 (11.1) 1.6 0.2
  • Infected abscess
1 (0.6) 0 (0.0) 0.1 0
  • Sterile abscess
1 (0.6) 0 (0.0) 0.1 0
  • Nodule
10 (6.2) 0 (0.0) 0.9 0
  • Pain/redness/swelling
53 (32.9) 0 (0.0) 4.8 0
Neurologic events Total 6 (3.7) 4 (66.7) 0.5 0.4
  • Convulsions/seizures
5 (3.1) 3 (60.0) 0.5 0.3
  • Encephalopathy/encephalitis
1 (0.6) 1 (100.0) 0.1 0.1
Other events of interest Total 14 (8.7) 1 (7.1) 1.3 0.1
  • Arthritis/arthralgia
1 (0.6) 0 (0.0) 0.1 0
  • Syncope with injury
1 (0.6) 0 (0.0) 0.1 0
  • Other severe/unusual events
12 (7.5) 1 (8.3) 1.1 0.1
Systemic events Total 69 (42.9) 5 (7.2) 6.2 0.5
  • Fever ≥38°C
18 (11.2) 4 (22.2) 1.6 0.4
  • Persistent crying/screaming
1 (0.6) 0 (0.0) 0.1 0
  • Rash
60 (37.3) 1 (1.7) 5.4 0.1
  • Severe vomiting/diarrhea
2 (1.2) 1 (50.0) 0.2 0.1

MMRV vaccine AEFIs

There were eight confirmed AEFI reports following MMRV vaccine administered between August 8, 2011, and December 31, 2013. The reporting rate was 8.7 per 100,000 doses distributed. The median age was 5 years (range: 1 to 10 years). MMRV vaccine was administered alone in four of the eight reports. The most common events were injection site reactions (n=4) and allergic reactions (n=2) (including one anaphylaxis); none were serious.


This analysis found a significant reduction in varicella disease incidence at a population level and a low AEFI reporting rate following the introduction of the publicly funded varicella vaccine program in Ontario.

Aggregate varicella reporting

Aggregate reporting of varicella was valuable in describing the overall trends in the epidemiology of disease in Ontario, despite data limitations described further below. The significant decrease in varicella incidence over the study period is consistent with findings observed in the U.S.Footnote 27Footnote 28 and suggests that the publicly funded immunization program has had a positive impact on reducing varicella disease incidence in Ontario. This is further demonstrated by comparing the pre- and post-program periods, where the incidence was over three and a half times higher in the pre-program period than in the post-program period. It should also be noted that the pre-program period includes the years when the varicella vaccine was available for private purchase in Canada (1998-2004) which is a conservative measure as it would minimize the magnitude of decrease in disease incidence between the pre- and the post-program periods if a decrease in disease burden occurred as a result of private vaccine availability. Although the trends in varicella-associated health care utilization were out of scope for this analysis, the decrease in disease incidence mirrors the trends in decreasing varicella-associated hospitalizations observed in Canadian provinces, including OntarioFootnote 7Footnote 8Footnote 9. Furthermore, the declining incidence observed across all age groups, including those not targeted by the publicly funded immunization program (i.e., infants under 1 year of age), suggests a herd effect.

We would expect that a toddler vaccination program would change the age distribution of disease by shifting the burden of disease towards older individuals. In both the pre- and post-program periods, the majority of the varicella cases were observed among the 5- to 9-year-old age group. However, in the post-program period, more cases were reported in the 10- to 14-year-old age group than in the 1- to 4-year-old age group, in contrast to what was observed in the pre-program period. We may continue to see this shift in age distribution in the future as both the vaccinated cohort and the population with naturally-acquired immunity age, and as varicella vaccine coverage of the younger cohort increases. The significant decrease in varicella incidence since the implementation of the two-dose program in 2011 warrants further consideration on future requirements for varicella reporting in Ontario.

Reported adverse events following immunization

AEFIs reported following varicella-containing vaccines administered in Ontario between 2010 and 2013 were consistent with the safety profile of varicella vaccines with no identification of any safety signals. The overall reporting rate of AEFIs following varicella vaccine (14.6 per 100,000 doses distributed) was comparable to reporting rates following other childhood vaccines administered in the second year of life in OntarioFootnote 29; however, it is lower than the AEFI reporting rates for varicella vaccine from the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) (74.0 per 100,000 doses distributed)Footnote 30 as well as passive AEFI surveillance systems in the U.S. and Europe (30.0 and 52.7 per 100,000 doses distributed, respectively)Footnote 19Footnote 20. The increase in the number of AEFI reports between 2010 and 2013 was anticipated given the expansion of the varicella immunization program in 2011.

Reported events were mostly mild (e.g., injection site reactions) and, as expected, rash was the most commonly reported event (37.3% of reports) which is consistent with observations from the U.S. and Europe (32.6% and 25.7%, respectively)Footnote 19Footnote 20. Among all rashes, we identified a subset as varicella-like (vesicular) rash through key-word searching, although it is not clear if these were due to wild-type or vaccine strain as none were laboratory-confirmed. In addition, we identified a single report of laboratory-confirmed vaccine-strain herpes zoster, an event which, while rare, has consistently been noted in post-marketing surveillance reportsFootnote 18Footnote 19Footnote 20Footnote 21. Serious AEFI reports were infrequently reported and were generally related to known, but rare, reactions to varicella vaccine, including cerebellar ataxia, which has been reported following both wild-type varicella infection and after varicella vaccine administrationFootnote 18Footnote 19Footnote 20Footnote 21Footnote 31. The reporting rate of cerebellar ataxia following varicella vaccine was low (0.18 per 100,000 doses distributed), and similar to the rates from other post-marketing surveillance systemsFootnote 18Footnote 19Footnote 20. No new or previously unknown serious events were reported.

Findings on MMRV vaccine are limited due to the low distribution of MMRV vaccine in the publicly funded program to date. As the use of this vaccine increases, an increase in AEFI reporting is expected and will contribute towards further understanding of the safety profile of this vaccine in Ontario.


Some limitations are inherent to many passive surveillance systems, including missing/incomplete data, reporting bias and under-reporting. In addition, the scope of this analysis is limited to only two out of three components of a comprehensive immunization program evaluation.

In terms of aggregate varicella reporting, under-reporting due to failure to report at the parent, physician, and/or PHU level would underestimate the burden of varicella in Ontario; however, the degree of under-reporting is not known. Additionally, because cases reported in aggregate cannot be reconciled with individual-level data (e.g., laboratory results, immunization data), data may include misclassified cases and some duplicate cases reported from more than one source. However, it is difficult to estimate the significance of duplicates and case misclassification without individual-level data.

For AEFI surveillance data, there was limited comparison to baseline rates, limited temporal trend analysis and lack of a population-based immunization registry. In addition, it has been noted elsewhereFootnote 29 that Ontario's overall AEFI reporting rate is less than half the national AEFI reporting rate, which is likely related to some degree of under-reporting as well as differences in AEFI reporting requirements in Ontario compared with other jurisdictions. With respect to varicella vaccine, pre-vaccination counselling about expected events following vaccine may also result in under-reporting of mild reactions specifically (i.e., fever, rash, injection site reactions), some of which are reportable as AEFIs in Ontario.


Varicella disease incidence was significantly reduced following the introduction of the publicly funded varicella vaccine program in Ontario and no safety signals were identified. These findings contribute towards varicella immunization program evaluation in Ontario which is essential to ensure the continued success of the program. Surveillance is ongoing to further assess trends in varicella disease and AEFI reporting in the context of the recent change from a one- to a two-dose schedule.


We would like to extend our sincere thanks to public health unit staff across the province for their efforts in investigation and reporting of varicella and adverse events following immunization which are essential to the assessment of the publicly funded program and vaccine safety in Ontario.

Conflict of interest



Funding for this project was provided by Public Health Ontario.

Page details

Date modified: